Market Size of Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry
Study Period | 2017- 2028 |
Base Year For Estimation | 2022 |
Forecast Data Period | 2023 - 2028 |
Market Size (2023) | USD 1.74 Billion |
Market Size (2028) | USD 1.99 Billion |
CAGR (2023 - 2028) | 2.73 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis
The Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Market size is expected to grow from USD 1.74 billion in 2023 to USD 1.99 billion by 2028, at a CAGR of 2.73% during the forecast period (2023-2028).
The COVID-19 pandemic positively impacted the European Dipeptide Peptidase 4 (DPP-4) Inhibitors Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. In the current crisis, type 2 diabetes patients are at much higher risk.
According to the diabetes category, the estimated cost per hospital admission during the first wave of COVID-19 in Europe ranged from EUR 25,018 for type 2 diabetes patients in good glycemic control to EUR 57,244 for type 1 diabetes patients in poor glycemic control, reflecting a higher risk of intensive care, ventilator support, and a longer hospital stay. The estimated cost for patients without diabetes was EUR 16,993. The expected total direct expenditures for COVID-19 secondary care in Europe were 13.9 billion euros. Diabetes treatment thus accounted for 23.5% of total expenditures.
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and are used in the treatment of type 2 diabetes. DPP4 inhibitors increase insulin and GLP-1 secretion and are commonly prescribed for people suffering from type 2 diabetes. The use of DPP4 inhibitors in patients with COVID-19 with or even without type 2 diabetes offers a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed with COVID-19 infection. Technological advancements have increased over the period leading to several modifications either in the DPP-4 Inhibitor drugs or the formulations being developed.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.